This article was published before automated invoicing was introduced in 2016.
Some functions may not work as intended.
Please contact us if you need more information.
According to the EvaluatePharma review of biotech and pharma industry in 2012, four out of five top biotech launches are not selling as expected.
The report also addresses the record number of FDA approvals of novel medicines (43 in 2012) and analyses market performance, VC funding, licensing deals, M&A transactions etc.
Did you like this article? Sign up with Life Science Network.
If you already have a Life Science Network account,
sign in,
or connect with LinkedIn,
Google.
